Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 17Melanoma 3Glioma 3Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Multiple Endocrine Neoplasia Type 1 2Diffuse Intrinsic Pontine Glioma 2Thymus Neoplasms 1Teratoma 1Solid Tumors Harboring a BRAF V600 Mutation 1Rhabdoid Tumor 1Osteitis Deformans 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Mesothelioma 1Medulloblastoma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Glioblastoma 1Familial ependymoma 1Fallopian Tube Neoplasms 1Estrogen Receptor and/or Progesterone Receptor Positive 1Cystadenocarcinoma, Serous 1Carcinoma, Hepatocellular 1

Interventions

Paclitaxel 2Letrozole 2trametinib 1ribociclib 1liposomal doxorubicin 1Topotecan 1Taxes 1Tamoxifen 1Doxorubicin 1Diphenhydramine 1Dexamethasone 1Cimetidine 1Axitinib 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Cystadenocarcinoma, Serous × ribociclib × Clear all
NCT03673124 2025-12-23

Ribociclib and Letrozole Treatment in Ovarian Cancer

GOG Foundation

Phase 2 Active not recruiting
51 enrolled 19 charts

Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡